ArticleCNS drugs2026

Correction: An Open‑Label Extension Study Assessing the Long‑Term Safety and Efficacy of Viloxazine Extended‑Release Capsules in Adults with Attention‑Deficit/Hyperactivity Disorder.

Ann Childress et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.